Compare Kyndryl Holdings Inc (KD) vs Eli Lilly And Co (LLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kyndryl Holdings Inc vs Eli Lilly And Co — how do they compare? Kyndryl Holdings Inc trades at $11.75 (market cap $2.59B), while Eli Lilly And Co trades at $1,177.75 (market cap $1.04T). The key difference: Eli Lilly And Co is far larger — about 401.5× Kyndryl Holdings Inc's market cap, and Eli Lilly And Co pays a 0.59% dividend while Kyndryl Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Kyndryl Holdings Inc for 36 Days and Eli Lilly And Co for 93 Days on average.
| KD | LLY | |
|---|---|---|
Market Cap | $2.59B | $1.04T |
Volume | 5,354,348 | 3,064,878 |
Sector | Technology | Health |
52-Week High | $29.76 | $1.28K |
52-Week Low | $10.59 | $799.57 |
Typical Hold Time | 36 Days | 93 Days |
Enterprise Value | $5.41B | $1.09T |
Dividend Yield | — | 0.59% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Kyndryl (KD) trades at $11.75, up 2.62% with bearish technical signals but improving fundamentals. The company reported positive net income of $252M in 2025 after years of losses, with revenue stabilizing around $15B. Recent news highlights AI initiatives including a new Dallas innovation lab and healthcare IT acquisition. Analyst consensus is mixed with 71% hold ratings but a $14.67 price target suggesting 25% upside potential.
KD shows fundamental improvement with profitability returning, though earnings misses and competitive pressures remain risks. The stock trades at reasonable valuations (P/S 0.18x) but faces execution challenges in its AI transformation. Institutional interest is building with recent purchases, but technical weakness suggests near-term consolidation likely before sustained upward movement.
Eli Lilly (LLY) trades at $1,179.27, down 0.79% on the day, with a bullish technical outlook and strong fundamental momentum. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $8.38 surpassing the $6.40 expectation. Revenue surged to $65.18 billion in 2025, driving a net income margin of 33.53%. Recent news highlights promising pipeline developments in weight-loss and diabetes drugs, reinforcing its market leadership.
The outlook remains positive given robust revenue growth, high profitability, and analyst consensus favoring buys. Key risks include competitive pressures in the obesity drug market and execution challenges in scaling production. With a consensus price target of $1,350, representing ~14% upside, the stock offers growth potential but requires monitoring of pipeline progress and market dynamics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kyndryl Holdings Inc
Kyndryl Holdings Inc is a technology services and infrastructure services provider company. It provides advisory, implementation, and managed services across a range of technology domains to help customers manage and modernize enterprise IT environments in support of their business and transformation objectives.
Read more on KD →About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →
